Labeled fibroblast activation protein inhibitor and use thereof
By targeting fibroblast activating protein (FAP) with compounds that chelate with radionuclides, the limited therapeutic effects of FAP targeting in existing technologies have been addressed, enabling efficient diagnosis and treatment of diseases with upregulated FAP expression.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- TIANJIN HENGRUI MEDICINE CO LTD
- Filing Date
- 2026-01-06
- Publication Date
- 2026-07-16
AI Technical Summary
Existing therapies targeting fibroblast activating protein (FAP) have limited effectiveness in cancer and other diseases, necessitating the development of more effective inhibitors and diagnostic tools.
A compound or a pharmaceutically acceptable salt thereof is provided for use in the preparation of medicaments for the diagnosis or treatment of diseases by complexation with a radionuclide, particularly by complexation with 161Tb or 212Pb for targeting diseases with upregulated expression of fibroblast activating protein (FAP).
It has achieved efficient diagnosis and treatment of diseases with upregulated FAP expression, especially imaging and treatment effects in tumors, inflammatory diseases, cardiovascular diseases and fibrotic diseases.
Smart Images

Figure CN2026070772_16072026_PF_FP_ABST